Compare Stocks: CHRS, DBVT, ACRS, and SLN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$5.95 -3.7%	$5.74	$1.74 ▼ $6.60	$864.11M	0.79	1.66 million shs	1.39 million shs
CHRS Coherus Oncology	$1.37 -3.5%	$1.40	$1.09 ▼ $2.62	$219.39M	0.94	1.36 million shs	437,194 shs
DBVT DBV Technologies	$13.70 +0.7%	$14.63	$8.70 ▼ $26.18	$855.73M	-0.95	269,775 shs	145,248 shs
SLN Silence Therapeutics	$14.79	$11.97	$4.19 ▼ $17.58	$890.50M	1.45	1.93 million shs	572,405 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	-3.72%	-3.41%	-0.50%	+36.47%	+188.83%
CHRS Coherus Oncology	-3.52%	-6.16%	-7.43%	-5.52%	+8.73%
DBVT DBV Technologies	+0.66%	-4.93%	-0.07%	-17.42%	+50.38%
SLN Silence Therapeutics	0.00%	+9.96%	+32.41%	+139.71%	+195.21%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$5.95 -3.7%	$5.74	$1.74 ▼ $6.60	$864.11M	0.79	1.66 million shs	1.39 million shs
CHRS Coherus Oncology	$1.37 -3.5%	$1.40	$1.09 ▼ $2.62	$219.39M	0.94	1.36 million shs	437,194 shs
DBVT DBV Technologies	$13.70 +0.7%	$14.63	$8.70 ▼ $26.18	$855.73M	-0.95	269,775 shs	145,248 shs
SLN Silence Therapeutics	$14.79	$11.97	$4.19 ▼ $17.58	$890.50M	1.45	1.93 million shs	572,405 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	-3.72%	-3.41%	-0.50%	+36.47%	+188.83%
CHRS Coherus Oncology	-3.52%	-6.16%	-7.43%	-5.52%	+8.73%
DBVT DBV Technologies	+0.66%	-4.93%	-0.07%	-17.42%	+50.38%
SLN Silence Therapeutics	0.00%	+9.96%	+32.41%	+139.71%	+195.21%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$11.33	90.48% Upside
CHRS Coherus Oncology	2.75	Moderate Buy	$8.67	532.60% Upside
DBVT DBV Technologies	2.71	Moderate Buy	$48.50	254.01% Upside
SLN Silence Therapeutics	2.83	Moderate Buy	$53.50	261.73% Upside

Current Analyst Ratings Breakdown

Latest CHRS, DBVT, ACRS, and SLN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	ACRS Aclaris Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
9/1/2026	ACRS Aclaris Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
8/11/2026	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$25.00 ➝ $32.00
8/7/2026	CHRS Coherus Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
7/17/2026	DBVT DBV Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	SLN Silence Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/30/2026	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/30/2026	DBVT DBV Technologies	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$47.00 ➝ $55.00
6/29/2026	DBVT DBV Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	ACRS Aclaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	SLN Silence Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$7.83M	106.25	N/A	N/A	$0.89 per share	6.69
CHRS Coherus Oncology	$42.17M	5.02	N/A	N/A	$0.39 per share	3.51
DBVT DBV Technologies	$5.64M	152.74	N/A	N/A	$2.55 per share	5.37
SLN Silence Therapeutics	$560K	1,590.19	N/A	N/A	$0.64 per share	23.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$64.92M	-$0.58	N/A	N/A	N/A	-921.50%	-61.65%	-42.41%	11/5/2026 (Estimated)
CHRS Coherus Oncology	$168.02M	-$1.03	N/A	N/A	N/A	-259.41%	-222.75%	-52.11%	11/5/2026 (Estimated)
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
SLN Silence Therapeutics	-$88.61M	-$1.28	N/A	N/A	N/A	-8,943.86%	-106.94%	-47.99%	11/5/2026 (Estimated)

Latest CHRS, DBVT, ACRS, and SLN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	SLN Silence Therapeutics	-$0.1387	-$0.26	-$0.1213	-$0.27	$1.13 million	N/A
8/6/2026	Q2 2026	ACRS Aclaris Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	$1.38 million	$1.63 million
8/5/2026	Q2 2026	CHRS Coherus Oncology	-$0.25	-$0.19	+$0.06	-$0.13	$14.41 million	$14.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
CHRS Coherus Oncology	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.46	3.46
CHRS Coherus Oncology	0.61	1.77	1.70
DBVT DBV Technologies	N/A	3.72	3.72
SLN Silence Therapeutics	N/A	7.42	7.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
CHRS Coherus Oncology	72.82%
DBVT DBV Technologies	71.74%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	4.80%
CHRS Coherus Oncology	7.22%
DBVT DBV Technologies	1.06%
SLN Silence Therapeutics	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	139.82 million	133.11 million	Optionable
CHRS Coherus Oncology	330	154.50 million	143.35 million	Optionable
DBVT DBV Technologies	80	62.88 million	62.21 million	Optionable
SLN Silence Therapeutics	100	60.21 million	58.40 million	Not Optionable

CHRS, DBVT, ACRS, and SLN Headlines

Recent News About These Companies

Silence Therapeutics to Participate in Three September Investor Conferences

September 2 at 10:16 AM | cityam.com

Silence Therapeutics (NASDAQ:SLN) Stock Price Up 5.8% - Should You Buy?

September 1 at 3:59 PM | marketbeat.com

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 31, 2026 | marketbeat.com

5AM Venture Management LLC Makes New Investment in Silence Therapeutics PLC Sponsored ADR $SLN

August 26, 2026 | marketbeat.com

Silence Therapeutics: Making Some Recent Noise

August 19, 2026 | seekingalpha.com

Silence Therapeutics (NASDAQ:SLN) Sees Strong Trading Volume - Should You Buy?

August 18, 2026 | marketbeat.com

What is HC Wainwright's Estimate for SLN Q3 Earnings?

August 18, 2026 | marketbeat.com

Investors Buy High Volume of Silence Therapeutics Call Options (NASDAQ:SLN)

August 17, 2026 | marketbeat.com

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs

August 14, 2026 | businesswire.com

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

August 14, 2026 | cityam.com

Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know

August 13, 2026 | zacks.com

Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Silence Therapeutics (SLN)

August 12, 2026 | theglobeandmail.com

Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley

August 12, 2026 | theglobeandmail.com

Silence Therapeutics (NASDAQ:SLN) Shares Down 6.9% - What's Next?

August 12, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Silence Therapeutics (SLN), Hims & Hers Health (HIMS) and Syndax Pharmaceuticals (SNDX)

August 12, 2026 | theglobeandmail.com

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

August 11, 2026 | businesswire.com

Morgan Stanley maintains Overweight rating on Silence Therapeutics

August 11, 2026 | seekingalpha.com

Silence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading Volume - What's Next?

August 11, 2026 | marketbeat.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera - Slideshow

August 11, 2026 | seekingalpha.com

Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial

August 11, 2026 | marketbeat.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript

August 10, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS, DBVT, ACRS, and SLN Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$5.95 -0.23 (-3.72%)

As of 09/3/2026 04:00 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Coherus Oncology NASDAQ:CHRS

$1.37 -0.05 (-3.52%)

As of 09/3/2026 04:00 PM Eastern

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

DBV Technologies NASDAQ:DBVT

$13.70 +0.09 (+0.66%)

As of 09/3/2026 04:00 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Silence Therapeutics NASDAQ:SLN

$14.79 0.00 (0.00%)

As of 09/3/2026 04:00 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CHRS, DBVT, ACRS, and SLN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CHRS, DBVT, ACRS, and SLN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CHRS, DBVT, ACRS, and SLN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS, DBVT, ACRS, and SLN Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Coherus Oncology NASDAQ:CHRS

DBV Technologies NASDAQ:DBVT

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CHRS, DBVT, ACRS, and SLN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CHRS, DBVT, ACRS, and SLN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CHRS, DBVT, ACRS, and SLN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS, DBVT, ACRS, and SLN Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Coherus Oncology NASDAQ:CHRS

DBV Technologies NASDAQ:DBVT

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools